That's because it is already in the process of running the ongoing phase 3 LEVEL study and is set to begin the second phase 3 study soon in 2025. Both of these late-stage studies are using this ...

PRINCETON, N.J., April 14, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients ...

Ironwood Pharmaceuticals is mulling its options after the FDA demanded another phase 3 trial before it will make an approval decision on the biopharma’s long-acting GLP-2 analog. The drug ...

Tem­pest Ther­a­peu­tics is mulling its busi­ness op­tions, in­clud­ing po­ten­tial ex­it path­ways, af­ter an in­abil­i­ty to raise cash to bankroll its lead can­cer as­set ...

Today, Johnson & Johnson announced promising new phase 3 data for icotrokinra (JNJ-2113), a first-in-class oral interleukin (IL)-23 receptor antagonist, showing that 75% of adolescents with ...

“Dosing the first patient in our global Phase 3 program is a major advancement as we work to deliver a differentiated, next-generation therapy for HCV,” said Jean-Pierre Sommadossi ...